secwatch.observer — SEC 8-K summary
======================================

Issuer:     Entrada Therapeutics, Inc. (TRDA)
CIK:        0001689375
Form:       8-K
Filed at:   2024-06-24T23:59:59+00:00
Accession:  0001104659-24-074130
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Entrada Therapeutics raises $100M in registered direct offering to fund pipeline
--------------------------------------------------------------------------------

- Gross proceeds of $100M from sale of 3,367,003 shares at $14.85 and pre-funded warrants at $14.8499.
- Offering led by U.S. healthcare-focused investor, two global mutual funds, and Janus Henderson.
- Proceeds to fund Phase 2b trials for ENTR-601-44/45 and Phase 2 MAD trial for ENTR-601-50.
- Expected closing on June 25, 2024; cash runway extended into 2027.
- 30-day lockup on new equity issuance and registration statements.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689375/000110465924074130/0001104659-24-074130-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689375/000110465924074130/tm2417848d3_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-074130

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer